Refine by
Preclinical Testing Services In Israel
5 services found
by:Champions Oncology, Inc. based inHackensack, NEW JERSEY (USA)
Champions Oncology has created screens that enroll each month in either In vivo, Ex Vivo or In vitro platforms. These screens allow for a significant cost savings compared to running stand-alone studies as well as provide free access to Standard of Care response data and other characterization data for each model. Check back frequently to learn more about each screen and to enroll in any active ...
by:Champions Oncology, Inc. based inHackensack, NEW JERSEY (USA)
Champions Oncology’s Analytical Testing platforms can be used to gather additional data at the endpoint of a preclinical model or ex vivo assay. Using multiplex cytokine assays with flow cytometry readouts, immune cell cytokine intracellular and extracellular staining upon activation can be assessed. ...
Manufactured by:Sartorius AG based inGoettingen, GERMANY
A more seamless transition into the clinic. Complex biopharmaceuticals and advanced therapies can present challenges during preclinical development. When implementing an albumin-based solution, Albumedix can help avoid unnecessary complications in your preclinical testing by creating species-specific recombinant albumins to suit your ...
Manufactured by:Sartorius AG based inGoettingen, GERMANY
One size doesn’t fit all – let's find a solution that fits your needs. With our longstanding albumin heritage, we can utilize our knowledge and expertise to produce a recombinant albumin as unique as your product and application demand. From bespoke formulations to alternative presentations, our dedicated recombinant human albumin GMP manufacturing facilities can meet your needs. ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
Graft Versus Host Disease (GvHD) is a potentially lethal complication of hematopoietic cell transplantation (HCT) from a donor. When a patient receives a donor’s stem cells, the transplanted cells may identify the patient’s body as foreign and attack it. The chronic form of GvHD occurs at least 100 days following the transplantation. The GvHD market is predicted to exceed $500 million ...